Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Non-Malignant Channel is supported with funding from Agios (Gold).

The Sickle Cell Disease Channel is supported with funding from Agios (Gold).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

BSH 2019 | Effectiveness of hydroxyurea in pediatric SCD in the real world

Subarna Chakravorty • 2 Apr 2019
BSH 2019
Non-Malignant Sickle Cell Disease Hydroxyurea

Subarna Chakravorty, MBBS, FRCPath, MRCPCH, PhD, King’s College Hospital NHS Foundation Trust, London, UK, speaks at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK. She discusses the effectiveness of hydroxyurea in children with sickle cell disease (SCD) via analysis of dose-response metrics in a large birth cohort in a tertiary SCD center.

More from Subarna Chakravorty

Acute chest syndrome in sickle cell disease: pathophysiology, management, and prevention
4:49
Acute chest syndrome in sickle cell disease: pathophysiology, management, and prevention
Subarna Chakravorty • 3 Nov 2025
The role of inflammation in SCD pathophysiology and potential avenues for targeting it
6:48
The role of inflammation in SCD pathophysiology and potential avenues for targeting it
Subarna Chakravorty • 3 Nov 2025
Transplantation and gene therapy in SCD and thalassemia: donor types and indications
10:55
Transplantation and gene therapy in SCD and thalassemia: donor types and indications
Subarna Chakravorty • 3 Nov 2025
Should MRI brain assessment be routinely performed in all patients with sickle cell disease?
5:05
Should MRI brain assessment be routinely performed in all patients with sickle cell disease?
Subarna Chakravorty • 3 Nov 2025

Related Videos

Safety and efficacy of etavopivat in adolescents with SCD: the ongoing HIBISCUS Kids trial
3:10
Safety and efficacy of etavopivat in adolescents with SCD: the ongoing HIBISCUS Kids trial
Subarna Chakravorty • 8 Dec 2025
A case report used to evaluate gene therapy outcomes in transfusion-dependent β-thalassemia
1:54
A case report used to evaluate gene therapy outcomes in transfusion-dependent β-thalassemia
Subarna Chakravorty • 2 Dec 2025
Exciting and potentially practice-changing hemophilia updates from ASH 2025
1:59
Exciting and potentially practice-changing hemophilia updates from ASH 2025
Subarna Chakravorty • 12 Dec 2025
Plasma-derived VWF/FVIII prophylaxis in children under 6 with VWD: first results from WIL-33
2:51
Plasma-derived VWF/FVIII prophylaxis in children under 6 with VWD: first results from WIL-33
Subarna Chakravorty • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals